Grifols, S.A.
Grifols, S.A. is a biotechnology company focused on the development and commercialization of plasma-derived and recombinant biological medicines.
Stock Performance Snapshot
Financial Health
Grifols is showing solid revenue and cash flow, indicating good overall financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring GRFS
The Plasma Profit Pipeline
Biopharmaceutical leader CSL reported a 14% surge in annual profit, fueled by its plasma division's success. This highlights a growing investment opportunity in companies involved in the plasma-derived therapies market and the broader bioprocessing supply chain.
Published: August 19, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Plasma as core
An extensive plasma‑collection network underpins sales of immunoglobulins and other therapies; supply and pricing can vary, which affects revenue.
Global footprint
Operations across Europe, the Americas and Asia offer market diversification but add currency and regulatory complexity for investors to monitor.
Balance‑sheet focus
Manufacturing and past acquisitions have resulted in notable indebtedness, so cash flow and debt metrics are closely watched by analysts.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Eli Lilly and Company
Eli Lilly & Co is a global pharmaceutical company that develops, manufactures and markets human prescription drugs.
Johnson & Johnson
Johnson & Johnson is a multinational conglomerate pharmaceutical, medical devices, and consumer packaged goods company.
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
